Nature Communications (Aug 2019)
Identification of drug-specific public TCR driving severe cutaneous adverse reactions
- Ren-You Pan,
- Mu-Tzu Chu,
- Chuang-Wei Wang,
- Yun-Shien Lee,
- Francois Lemonnier,
- Aaron W. Michels,
- Ryan Schutte,
- David A. Ostrov,
- Chun-Bing Chen,
- Elizabeth Jane Phillips,
- Simon Alexander Mallal,
- Maja Mockenhaupt,
- Teresa Bellón,
- Wichittra Tassaneeyakul,
- Katie D. White,
- Jean-Claude Roujeau,
- Wen-Hung Chung,
- Shuen-Iu Hung
Affiliations
- Ren-You Pan
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou
- Mu-Tzu Chu
- Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Immunology Consortium, Chang Gung Memorial Hospital
- Chuang-Wei Wang
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou
- Yun-Shien Lee
- Department of Biotechnology, Ming Chuan University
- Francois Lemonnier
- INSERM U1016, Institut Cochin, Equipe Immunologie du Diabète, Hôpital Saint-Vincent-de-Paul
- Aaron W. Michels
- Barbara Davis Center for Childhood Diabetes, University of Colorado Denver
- Ryan Schutte
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine
- David A. Ostrov
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine
- Chun-Bing Chen
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou
- Elizabeth Jane Phillips
- Departments of Medicine and Pathology, Microbiology and Immunology, School of Medicine, Vanderbilt University
- Simon Alexander Mallal
- Departments of Medicine and Pathology, Microbiology and Immunology, School of Medicine, Vanderbilt University
- Maja Mockenhaupt
- Dokumentationszentrum schwerer Hautreaktionen (dZh), Department of Dermatology, Medical Center and Medical Faculty, University of Freiburg
- Teresa Bellón
- Research Unit, Hospital Universitario La Paz-Idi PAZ
- Wichittra Tassaneeyakul
- Department of Pharmacology, Faculty of Medicine, Khon Kaen University
- Katie D. White
- Departments of Medicine and Pathology, Microbiology and Immunology, School of Medicine, Vanderbilt University
- Jean-Claude Roujeau
- Emeritus Professor of Dermatology, Université Paris-Est Créteil (UPEC)
- Wen-Hung Chung
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou
- Shuen-Iu Hung
- Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Immunology Consortium, Chang Gung Memorial Hospital
- DOI
- https://doi.org/10.1038/s41467-019-11396-2
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 13
Abstract
Severe cutaneous adverse reactions (SCAR) is a T cell-mediated, potentially lethal drug hypersensitivity (DH). Here, the authors identify a carbamazepine-specific TCR common among patients with carbamazepine-induced SCAR that confers SCAR-like pathology in mice upon carbamazepine exposure, thereby implicating specific TCRs in DH etiology.
